Ranbaxy to sell vaccine business Biovel after facing loss
Ranbaxy decides to sell its Bangalore-based vaccine business Biovel, after incurring losses worth $7.8 million in the quarter alone

Biovel was working in segments like cardiology, endocrinology, oncology, dermatology and gynaecology and also making typhoid and influenza vaccines
Bangalore: Ranbaxy is going to exit its Bangalore-based vaccine manufacturing company, Biovel, according to Business Standard. Ranbaxy acquired Biovel in 2010 marking its foray into the vaccine business.